To identify common genetic variants linked to aggressive prostate cancer, Koboldt and colleagues used whole-exome sequencing followed by targeted sequencing in aggressive prostate cancer patients and disease-free controls in both African and European Americans. In each population, the authors tested rare variants for association using two gene-based aggregation tests. TET2 in African Americans was associated with aggressive disease, with 24.4% of cases harboring a rare deleterious variant, compared to 9.6% of controls. Eight additional genes were identified with suggestive evidence of association as well as rare truncation variants. These findings suggest that rare variants influence risk of clinically relevant prostate cancer and if validated could serve to identify men for screening, prophylaxis, and treatment.

The effects of use of different types of hormone therapy (HT) on breast cancer risk according to prognostic factors are largely unknown. Román and colleagues linked data from the Norwegian Prescription Database and the...

You do not currently have access to this content.